Fennec Pharmaceuticals Announces New Investigator-Sponsored Study for PEDMARK® in Adult Cancers
FENC sits 35% above its 52-week low of $4.68.
Summary
Fennec Pharmaceuticals announced a new investigator-sponsored study for PEDMARK® to evaluate its use in AYA and adult patients with head and neck and testicular cancers, aiming to expand the drug's market and clinical evidence.
Key Events · Product Development and Regulatory · FENC
-
New Investigator-Sponsored Study Initiated
The University of Arizona Cancer Center has initiated a Phase I/II open-label trial to evaluate PEDMARK® (sodium thiosulfate injection) as an otoprotectant in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin chemotherapy.
-
Expansion of PEDMARK®'s Potential Use
This study aims to build real-world evidence and expand the understanding of PEDMARK®'s benefits beyond its current FDA-approved indication for pediatric patients, potentially supporting broader clinical adoption and future label expansion for AYA and adult cancer patients.
-
Ongoing Research Efforts
This new study follows the initiation of two other institution-led clinical studies announced in March 2026 and December 2025, demonstrating Fennec's commitment to supporting independent research for PEDMARK®.
Analysis · FENC · Life Sciences
Fennec Pharmaceuticals announced the initiation of a new investigator-sponsored study for its drug, PEDMARK®, at the University of Arizona Cancer Center. This study will evaluate PEDMARK® in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. This is a positive development as it expands the clinical evidence and potential market for PEDMARK® beyond its current pediatric indication, aligning with the company's strategy to support broader clinical adoption and potential label expansion. The company has recently announced other similar institution-led studies, indicating a concerted effort to build real-world data for its key product.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FENC was trading at $6.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.9M. The 52-week trading range was $4.68 to $9.92. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.